313 related articles for article (PubMed ID: 7786298)
1. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
2. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
Grigoriadis G; Stewart AG
Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
[TBL] [Abstract][Full Text] [Related]
3. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
Salari H; Dryden P; Howard S; Bittman R
Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
[TBL] [Abstract][Full Text] [Related]
4. Interactions between alkylglycerols and human neutrophil granulocytes.
Palmblad J; Samuelsson J; Brohult J
Scand J Clin Lab Invest; 1990 Jun; 50(4):363-70. PubMed ID: 2168089
[TBL] [Abstract][Full Text] [Related]
5. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
6. Effect of synthetic phospholipids on platelet aggregation and serotonin release.
Söling U; Eibl H; Nagel GA; Unger C
Lipids; 1987 Nov; 22(11):868-70. PubMed ID: 3444380
[TBL] [Abstract][Full Text] [Related]
7. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids.
Ostermann G; Hofmann B; Kertscher HP; Till U
Thromb Res; 1991 Feb; 61(3):261-9. PubMed ID: 2028445
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
11. The ether lipid ET-18-OCH3 increases cytosolic Ca2+ concentrations in Madin Darby canine kidney cells.
Jan CR; Wu SN; Tseng CJ
Br J Pharmacol; 1999 Jul; 127(6):1502-10. PubMed ID: 10455302
[TBL] [Abstract][Full Text] [Related]
12. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.
Foster AP; Lees P; Andrews MJ; Cunningham FM
Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830
[TBL] [Abstract][Full Text] [Related]
13. Selective activation of human monocytes by the platelet-activating factor analog 1-O-hexadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine.
Rose JK; Debs RA; Philip R; Ruis NM; Valone FH
J Immunol; 1990 May; 144(9):3513-7. PubMed ID: 2329280
[TBL] [Abstract][Full Text] [Related]
14. Effects of ether lipid 1-O-octadecyl-2-methoxy-rac-glycero- 3-phosphocholine and its analogs PAF and CPAF on the release of nitric oxide in primary cultures of rat astrocytes.
Cardile V; Jiang X; Renis M; Bindoni M
Brain Res; 1996 Apr; 715(1-2):98-103. PubMed ID: 8739627
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
da Silva MB; Herion F; Raskinet R; David JL; Gustin P; Dessy C; Lekeux P
Zentralbl Veterinarmed A; 1996 Sep; 43(7):399-413. PubMed ID: 8921726
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
17. The effect of ether lipid 1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine and its analogues platelet activating factor and carbamyl-platelet activating factor on the biosynthesis of interleukin-6 in human thymic epithelial cells cultivated in vitro.
Cardile V; Mascarucci P; De Simoni MG; Jiang X; Bindoni M
Cytokine; 1996 Sep; 8(9):698-701. PubMed ID: 8932980
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis.
Alonso MT; Gajate C; Mollinedo F; Modolell M; Alvarez J; García-Sancho J
Br J Pharmacol; 1997 Aug; 121(7):1364-8. PubMed ID: 9257915
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the actions of platelet activating factor (PAF) antagonists WEB 2170 and WEB 2086 in the horse.
Foster AP; Cunningham FM; Andrews MJ; Lees P
J Vet Pharmacol Ther; 1993 Dec; 16(4):477-87. PubMed ID: 8126765
[TBL] [Abstract][Full Text] [Related]
20. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking.
Lehr HA; Weyrich AS; Saetzler RK; Jurek A; Arfors KE; Zimmerman GA; Prescott SM; McIntyre TM
J Clin Invest; 1997 May; 99(10):2358-64. PubMed ID: 9153277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
